Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PURE BIOSCIENCE, INC.PURE · Entity 7969 | Director · Chairman of the Board | February 26, 2018 | March 01, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PURE BIOSCIENCE, INC.
Report date February 26, 2018 · Filed March 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2023-02-26 | Direct | 200,000 |
Reported balance
After 2018-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-26 · Grant · Acquired 200,000 · Balance 200,000 F1: 25% of the option shares shall vest and become exercisable in four equal quarterly installments beginning on May 26, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the option shares shall vest and become exercisable in four equal quarterly installments beginning on May 26, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2018 Filed Mar 1, 2018 00:19 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-014705 · doc4.xml · derivative · entry 1 Pfanzelter David J · CIK 0001569467 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2023-02-26 F1 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable in four equal quarterly installments beginning on May 26, 2018. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 22:17 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | Exercise / conversionWarrant · Derivative | 16,000 | Not disclosed Strike: $0.60 | Not disclosed |
DisclosureSEC source: 0001209191-17-054171 · doc4.xml · derivative · entry 4 Pfanzelter David J · CIK 0001569467 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2017-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: In accordance with the terms of the Issuer's tender offer, the Reporting Person exercised his 2014 Warrant in full and in cash on September 25, 2017. F2 · price: In accordance with the terms of the Issuer's tender offer, the Reporting Person exercised his 2014 Warrant in full and in cash on September 25, 2017. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 22:17 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantWarrant · Derivative | 16,000 | Not disclosed Strike: $0.60 | Not disclosed |
DisclosureSEC source: 0001209191-17-054171 · doc4.xml · derivative · entry 3 Pfanzelter David J · CIK 0001569467 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2017-09-25 F1 · kind: On September 25, 2017, the Issuer completed the initial closing of a tender offer in which the Issuer offered to amend the terms of the outstanding warrants the Issuer issued to investors participating in private placement financings the Issuer completed on August 29, 2014 (the "2014 Warrants"), on November 23, 2015 (the "2015 Warrants") and on January 23, 2017 (the "2017 Warrants"). As part of the tender offer and in order to raise funds to support its continued operations, the Issuer offered to reduce the respective exercise prices of the 2014, 2015 and 2017 Warrants if the holders agreed to exercise their Warrants in cash by September 25, 2017. The Reporting Person holds a 2014 Warrant and elected to participate in the Issuer's tender offer. As a result, the exercise price and the expiration date, among other terms, of the 2014 Warrant held by the Reporting Person were amended. F1 · price: On September 25, 2017, the Issuer completed the initial closing of a tender offer in which the Issuer offered to amend the terms of the outstanding warrants the Issuer issued to investors participating in private placement financings the Issuer completed on August 29, 2014 (the "2014 Warrants"), on November 23, 2015 (the "2015 Warrants") and on January 23, 2017 (the "2017 Warrants"). As part of the tender offer and in order to raise funds to support its continued operations, the Issuer offered to reduce the respective exercise prices of the 2014, 2015 and 2017 Warrants if the holders agreed to exercise their Warrants in cash by September 25, 2017. The Reporting Person holds a 2014 Warrant and elected to participate in the Issuer's tender offer. As a result, the exercise price and the expiration date, among other terms, of the 2014 Warrant held by the Reporting Person were amended. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 22:17 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | Disposition to issuerWarrant · Derivative | 16,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001209191-17-054171 · doc4.xml · derivative · entry 2 Pfanzelter David J · CIK 0001569467 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2019-07-02 F1 · kind: On September 25, 2017, the Issuer completed the initial closing of a tender offer in which the Issuer offered to amend the terms of the outstanding warrants the Issuer issued to investors participating in private placement financings the Issuer completed on August 29, 2014 (the "2014 Warrants"), on November 23, 2015 (the "2015 Warrants") and on January 23, 2017 (the "2017 Warrants"). As part of the tender offer and in order to raise funds to support its continued operations, the Issuer offered to reduce the respective exercise prices of the 2014, 2015 and 2017 Warrants if the holders agreed to exercise their Warrants in cash by September 25, 2017. The Reporting Person holds a 2014 Warrant and elected to participate in the Issuer's tender offer. As a result, the exercise price and the expiration date, among other terms, of the 2014 Warrant held by the Reporting Person were amended. F1 · price: On September 25, 2017, the Issuer completed the initial closing of a tender offer in which the Issuer offered to amend the terms of the outstanding warrants the Issuer issued to investors participating in private placement financings the Issuer completed on August 29, 2014 (the "2014 Warrants"), on November 23, 2015 (the "2015 Warrants") and on January 23, 2017 (the "2017 Warrants"). As part of the tender offer and in order to raise funds to support its continued operations, the Issuer offered to reduce the respective exercise prices of the 2014, 2015 and 2017 Warrants if the holders agreed to exercise their Warrants in cash by September 25, 2017. The Reporting Person holds a 2014 Warrant and elected to participate in the Issuer's tender offer. As a result, the exercise price and the expiration date, among other terms, of the 2014 Warrant held by the Reporting Person were amended. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 22:17 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | Exercise / conversionCommon Stock | 16,000 | $0.60 | $9,600.00 |
DisclosureSEC source: 0001209191-17-054171 · doc4.xml · nonDerivative · entry 1 Pfanzelter David J · CIK 0001569467 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 20:59 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Options (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-17-041856 · doc4.xml · derivative · entry 2 Pfanzelter David J · CIK 0001569467 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2027-06-22 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on December 31, 2018 with the remaining shares vesting in 3 equal annual installments thereafter. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 20:59 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041856 · doc4.xml · nonDerivative · entry 1 Pfanzelter David J · CIK 0001569467 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,000 F1 · shares: Represents the issuance of restricted stock units (the "RSUs"). 25% of the RSUs vest on December 31, 2018 with the remaining shares vesting in 3 equal annual installments thereafter. Vested shares will be delivered to the Reporting Person on the earlier of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee's Service ceases for any reason and such cessation constitutes a "separation from service" within the meaning of Section 409A of the Code; (iii) the date of Grantee's death or (iv) the date of a Change in Control that constitutes a "change in control event" within the meaning of Section 409A of the Code. F2 · balance_after: Reflects the cancellation of 2,800,000 Restricted Stock Units pursuant to an RSU Cancellation Agreement, dated December 13, 2016. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:28 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-17-017991 · doc4.xml · derivative · entry 1 Pfanzelter David J · CIK 0001569467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-03-01 F1 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on April 30, 2017, July 31, 2017, October 31, 2017 and January 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.